Notizie mediche e ricerca

In a 410-patient phase 3 double-blind RCT, 52 weeks of nicotinamide riboside increased MDS-UPDRS by 2.7 points relative to placebo and worsened nonmotor symptoms despite similar serious adverse event rates.

In a randomized clinical trial, oral nicotinamide riboside showed no clinical benefit and was linked to modestly worse outcomes than placebo, arguing against disease-modifying use.

Difference-in-differences analysis of 77,000 person-years in the UKHLS links UC introduction to a 0.94-point SF-12 MCS decline and a 3.8 percentage-point rise in probable depression, with larger effects in bigger families.

In a single-blinded individual RCT in rural Pakistan with 250 dyads, 15 monthly sessions increased OMCI scores by 12.3 points vs usual care and were associated with higher birth weight and better maternal distress and functioning at 12 months.